Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

NCT04884282 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG: Tedopi
DRUG: Nivolumab
DRUG: Docetaxel

Sponsor

Fondazione Ricerca Traslazionale